Centogene extends strategic partnership with takeda to continue providing access to genetic testing for patients with lysosomal storage disorders

Cambridge, mass. and rostock, germany and berlin, march 19, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with takeda (tse: 4502/nyse: tak) to diagnose patients with lysosomal storage disorders (lsds).
CNTG Ratings Summary
CNTG Quant Ranking